ClearPoint Neuro price target raised to $20 from $15 at B. Riley
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
BioSpace5 天
Atalanta Gets $97 Million Series B to Target Neurological Disorders With RNAi
The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on Twitter by northeasternsvf. In this article, we will ...
ClearPoint Neuro (CLPT) Gets a Buy from Lake Street
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on ClearPoint Neuro (CLPT – Research Report). The company’s ...
WDRB5 天
New neuro-stimulation treatment helping Kentuckians overcome addiction
A groundbreaking treatment for substance use disorder is changing lives by using neuro-stimulation, and it’s exclusively ...
Psychology Today1 天
Neurological Functions Associated with Acquired Brain Injury
In December 1993, former World Boxing Champion John Famechon, who had suffered a severe brain injury in August 1991, began participating in a new and novel multi-movement therapy ...
FierceBiotech5 天
Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
pressat5 天
Chilterns Neuro Centre forms new association with Laybrook
The Chilterns Neuro Centre has recently formed a new association with Laybrook, a manufacturer of custom-made specialist ...